- Home
- PROK vs ACRS Comparison
PROK vs ACRS Comparison
Compare PROK & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PROK | ACRS |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | 231 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.7M | 311.0M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PROK | ACRS |
|---|---|---|
| Price | $1.81 | $3.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $7.40 | ★ $9.75 |
| AVG Volume (30 Days) | 795.9K | ★ 2.6M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | $893,000.00 | ★ $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.00 | $4.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1075.00 | N/A |
| 52 Week Low | $0.46 | $1.05 |
| 52 Week High | $7.13 | $4.89 |
Technical Indicators
Market Signals| Indicator | PROK | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 57.67 |
| Support Level | $1.71 | $3.16 |
| Resistance Level | $2.58 | $4.89 |
| Average True Range (ATR) | 0.14 | 0.26 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 42.97 | 70.10 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.